This review will first summarize the early seminal research, which created conceptual and pre-clinical bases for the on-going clinical pharmacological and gene therapy strategies developed to use CYP46A1 as a therapeutic target to treat neurodegenerative diseases. Here, CYP46A1 is linked to neurodegenerative disease.